|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
..
Zengen, Inc.
6429 Independence Avenue
Woodland Hills
California
91367
U.S.A.
Phone:
818-887-8688
Fax:
818-884-5988
|
Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its patented peptide technologies. These technologies are based on an extensive background of over 25 years of academic research on peptide molecules derived from a-Melanocyte-Stimulating Hormone (a-MSH), an endogenous molecule that modulates inflammatory and immune responses.
Strategic Approach
Zengen's strategy is to demonstrate the capabilities of our patented peptide technologies and, where appropriate, enter into collaborative arrangements with other pharmaceutical companies that possess complementary capabilities, development resources or other assets. Zengen's development efforts are based on two distinctly separate and versatile approaches. The Company's primary approach is to develop CZEN 002, a synthetic octapeptide (Ac-Cys-Lys-Pro-Val-NH)2, that has broad application as an anti-infective prescription pharmaceutical agent, and to develop novel molecules for the Company's pharmaceutical product pipeline.
The second and parallel approach is to develop another Zengen molecule, LyProVal™, for a variety of applications in the consumer market. Zengen's strategy in this market is to rapidly develop products in the over-the-counter market using its patented peptide technology and thereby create value that can be converted into capital in the near term to finance the development of additional prescription biopharmaceutical products. Because of the broad applications of LyProVal™, the Company has multiple product candidates to develop and promote to a large number of potential buyers. In addition, Zengen will seek profitable in-licensing opportunities in its over-the-counter business. In this way, Zengen will be able to leverage its proven expertise in marketing over-the-counter products to capture revenue and to reduce dilution associated with equity financings or the constraints imposed by creditors in debt financings.
An important element of Zengen's business strategy is to control costs and overhead by entering into license agreements with other parties to share the risks and benefits of various stages of the drug development process. The Company focuses on the discovery and early-stage development of drug candidates and seeks to establish partnerships with pharmaceutical companies for late-stage development and commercialization of Zengen's peptides. This strategy should control the Company's expenses, minimize risks and allow the Company to have a greater number of attractive drug candidates progress to late-stage development.
Contact us by e-mail:
General information/collaborations/legal - mlipton@zengen.com
Investor Relations and Employment Opportunities - rdavidson@zengen.com
Scientific inquiries/peptides - jlipton@zengen.com
Business Development - bj@zengen.com
Last Updated: 08-08-02
Email:
rdavidson@zengen.com
Ownership:
Private
Web Site:
Zengen, Inc.
Employees:
Symbol:
|
|
|
Company News |
Migami, Inc. Acquires Zengen, Inc. Assets and Sublicenses Bi-Layer Film Strip Technology in Korea
1/9/2008 9:33:26 AM
More...
|
Zengen: New Weapon Against Yeast Infections Found
10/19/2005 5:11:32 PM
More...
|
Zengen, Inc. Reports Positive Phase I/II Trial Results Of its Proprietary Peptide Molecule For Vaginal Yeast Infection
10/19/2005 5:11:30 PM
More...
|
Zengen, Inc.'s New Study Reviews Novel Approach To Control Inflammation Using Melanocortin Receptors
10/19/2005 5:10:16 PM
More...
|
|
|
 |
|
|
|
|
|
|
|
|